Advertisement

 

 

Nonnucleoside Reverse Transcriptase Inhibitors Reduce HIV-1 Production from Latently Infected Resting CD4(+) T Cells following Latency Reversal.

Nonnucleoside Reverse Transcriptase Inhibitors Reduce HIV-1 Production from Latently Infected Resting CD4(+) T Cells following Latency Reversal.
Author Information (click to view)

Zerbato JM, Tachedjian G, Sluis-Cremer N,


Zerbato JM, Tachedjian G, Sluis-Cremer N, (click to view)

Zerbato JM, Tachedjian G, Sluis-Cremer N,

Advertisement

Antimicrobial agents and chemotherapy 2017 02 2361(3) pii 10.1128/AAC.01736-16

Abstract

Therapeutic strategies that target the latent HIV-1 reservoir in resting CD4(+) T cells of infected individuals are always administered in the presence of combination antiretroviral therapy. Using a primary cell of HIV-1 latency, we evaluated whether different antiviral drug classes affected latency reversal (as assessed by extracellular virus production) by anti-CD3/CD28 monoclonal antibodies or bryostatin 1. We found that the nonnucleoside reverse transcriptase inhibitors efavirenz and rilpivirine significantly decreased HIV-1 production, by ≥1 log.

Submit a Comment

Your email address will not be published. Required fields are marked *

7 − 6 =

[ HIDE/SHOW ]